Capricor Therapeutics, Inc. (CAPR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 34/100 (MEDIUM), 36.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 38.78% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
Recent News & SEC Filings
- CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
- Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
- Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
- CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
- Why Did CAPR Stock Jump 20% After-Hours Today?
- Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
- Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
- Sector Update: Healthcare Stocks Advance Late Afternoon
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Capricor Therapeutics, Inc..
Full CAPR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.